Skip to main
VNRX

Volitionrx Limited (VNRX) Stock Forecast & Price Target

Volitionrx Limited (VNRX) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

VolitionRX Ltd's positive outlook is supported by the potential for securing additional human licensing deals in 2026, which could enhance topline revenue growth, especially given the company's pioneering focus on circulating cell-free nucleoproteins in liquid biopsies. Encouraging early-stage cancer detection results, including detection rates of up to 100% for certain stages, bolster confidence in the Nu.Q platform's utility in clinical settings, particularly regarding acute care and chronic disease monitoring. Furthermore, the technology's ability to produce over 99% pure circulating tumor DNA datasets marks a significant advancement in detection accuracy, suggesting a promising trajectory for clinical adoption and revenue generation as larger validation studies are conducted.

Bears say

VolitionRX faces significant risks that contribute to a negative outlook on its stock, including possible failures in clinical development of its diagnostic products, securing necessary license agreements, and achieving market traction. The company's net loss of $23.4 million, translating to a loss of $0.22 per share, highlights ongoing financial challenges. Additionally, concerns regarding dilution, going concern, and potential delisting add further uncertainty to the company's financial stability and future prospects.

Volitionrx Limited (VNRX) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Volitionrx Limited and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Volitionrx Limited (VNRX) Forecast

Analysts have given Volitionrx Limited (VNRX) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Volitionrx Limited (VNRX) has a Strong Buy consensus rating as of Apr 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $2, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $2, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Volitionrx Limited (VNRX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.